CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 26 enrolled
Drug / intervention
FAI Insert administered using the Mk II inserter +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02748512
NCT02748512Phase 3Completed

A Controlled, Multi-Center Study of the Utilization and Safety of the MkII Inserter and the Safety of the FAI Insert in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye.

EyePoint Pharmaceuticals, Inc.·interventional·Posted Apr 22, 2016·Updated May 1, 2020

In Brief

A Phase 3 clinical trial evaluating FAI Insert administered using the Mk II inserter and FAI Insert administered using the Mk I inserter for Non-Infectious Uveitis. Completed, enrolled 26 participants across 6 sites.

Detailed Summary

This trial is a 12 month, Phase 3, multi-center, randomized, single-masked (subject), controlled study designed to evaluate the utilization and safety of the Mk II inserter and the safety of the FAI insert, in subjects with non-infectious uveitis affecting the posterior segment of the eye.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 22, 2016
Enrollment StartFeb 23, 2016
Primary CompletionAug 17, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 10.2 years ago

Interventions

FAI Insert administered using the Mk II inserterdrug

FAI Insert administered using the Mk I inserterdrug